Back to news

ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Globe Newswire•16/11/2026•08:00 ET
0

Key Highlights

  • ➤$147.2 million cash, equivalents and investments fund planned operations through first half of 2028
  • ➤ALX2004 Phase 1 safety and early efficacy data expected in December 2026
  • ➤ASPEN-09-Breast topline data from approximately 120 patients expected in second half of 2027
  • ➤Q3 GAAP net loss $21.8 million, or $0.15 per share
  • ➤ASPEN-06 results highlighted improved responses and durable benefit for evorpacept in HER2-positive gastric cancers

Expert Statements

Jason Lettmann, Chief Executive Officer of ALX Oncology

“Throughout the third quarter, we continued to make significant progress across both the ASPEN-09-Breast and ALX2004 clinical trials.”

Jason Lettmann, Chief Executive Officer of ALX Oncology

“The recent publication of ASPEN-06 results in Nature Medicine further reinforces the promise of evorpacept and our biomarker-driven development strategy.”

Jason Lettmann, Chief Executive Officer of ALX Oncology

“Enrollment in ASPEN-09-Breast remains robust, and we now expect to report topline data from approximately 120 patients in the second half of 2027.”

Jason Lettmann, Chief Executive Officer of ALX Oncology

“ALX2004 continues to advance as a differentiated EGFR-targeted ADC with the potential to address a broad range of EGFR-expressing solid tumors, and we look forward to reporting safety and early efficacy data from the ongoing Phase 1 study in December.”

Jason Lettmann, Chief Executive Officer of ALX Oncology

“With multiple clinical catalysts ahead, a differentiated pipeline, and a strong commitment to disciplined execution, we believe ALX Oncology is well positioned to create long-term value for both patients and shareholders.”

Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026

Topline data from 120 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer expected in 2H 2027

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in